Qiagen, based in Germany, has revealed that its NeuMoDx assay for human immunodeficiency virus type 1 (HIV-1) has obtained approval for utilization in Thailand. With the inclusion of the previously sanctioned hepatitis B virus (HBV) and hepatitis C virus (HCV) quantitative assays, Thailand now possesses a comprehensive range of blood-borne virus (BBV) assays.
The NeuMoDx HIV-1 Quant Assay is formulated to quantify and detect human immunodeficiency virus type 1 (HIV-1) RNA in human plasma. It serves as a tool in the clinical oversight of HIV-1 infected individuals, facilitating the monitoring of anti-retroviral treatment efficacy through assessment of plasma HIV-1 RNA levels. Additionally, it aids in diagnosing HIV-1 infection, including acute or primary infection.
Hepatitis B virus (HBV) DNA can be quantified in human plasma and serum specimens for HBV genotypes A through H in HBV-infected patients using the NeuMoDx HBV Quant Assay. It is meant to serve as a tool to help people with HBV infection choose the best course of treatment. Hepatitis C virus (HCV) RNA genotypes 1 through 6 can be quantified in human plasma and serum specimens from HCV antibody-positive people using the NeuMoDx HCV Quant Assay. Its purpose is to support the treatment of people infected with HCV.
The NeuMoDx system offers assays for respiratory disorders, sexual and reproductive health, and viruses linked to transplants in addition to blood-borne viruses.
QIAGEN N.V. is an international company with German roots that specializes in providing sample and assay technology for academic research, pharmaceutical research, applied testing, and molecular diagnostics. The business has operations in over 25 countries and over 35 offices.
